TaqNova DNA Polymerase

• Synthesizes DNA at extremely high temperatures
• Generates high yields with minimal amounts of enzyme and little optimization
• Possesses increased sensitivity and is suitable for a wide range of applications
• Amplifies fragments of up to 5 kb with a half-life of 45 minutes at 95°C
• Leaves ´A´ overhangs

TaqNova DNA Polymerase and TaqNova Polymerase UCP are a 94 kDa recombinant, thermostable Taq DNA polymerase isolated from Thermus aquaticus. It is recommended for a wide range of applications that require DNA synthesis at extremely high temperatures. It is a universal, easy-to-use DNA polymerase that works rapidly and effectively in various PCR conditions.

Both enzymes catalyze DNA synthesis in a 5’→3’ direction. It shows no 3’→ 5’ exonuclease activity but has 5’→ 3’ exonuclease activity.

Both enzymes are supplied with 20 mM Tris-HCl (pH 8.0 at 25°C), 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5% (v/v) Nonidet P40, 0.5% (v/v) Tween 20, 50% (v/v) glycerol.

One unit is defined as the amount of enzyme required to incorporate 10 nmol of dNTPs to an insoluble DNA fraction in 30 minutes at 75°C for TaqNova DNA Polymerase and at 72°C for TaqNova Polymerase UCP in a 50 μL reaction.

TaqNova DNA Polymerase UCP

Both reaction buffers provided may be used with TaqNova DNA polymerase.

10x TaqNova KCl
100 mM Tris-HCl (pH 8.8 at 25°C), 500 mM KCl, 0.8% (v/v) Nonidet P40

10x TaqNova (NH₄)₂SO₄
750 mM Tris-HCl (pH 8.8 at 25°C), 200 mM (NH₄) ₂SO₄, 0.1% (v/v) Tween 20

10x TaqNova KCl buffer is recommended as first approach and for applications requiring high specificity. 10x TaqNova (NH₄)₂SO₄ buffer is recommended for applications where high sensitivity and amplification efficiency is required (e.g. for amplification of multiple DNA fragments). Both buffers may be evaluated to determine the buffer most suitable for specific application.

Quality Control

The product was tested in PCR reaction, with a dilution series of polymerase and a dilution series of human genomic DNA. The product is free of unspecific DNA nucleases.

This is used for applications such as:

• Amplification of short and medium size DNA sequences
• Routine, Diagnostic and Multiplex PCR
• TA cloning

The acquisition of BLIRT by QIAGEN in the second quarter of 2022 paved the way for BLIRT’s expansion of R&D and manufacturing capabilities for customized and standardized recombinant enzymes and molecular biology reagents. Due to the transition, the rebranding process from BLIRT to QIAGEN is ongoing and the following resources still show BLIRT branding.
 
We assure you that the integration does not affect the quality, fit, form and function of the products.